CIR
Live / Applied — Third extension granted (statement of use) (as of 29 Dec 2025)
What this means for you
Not registered yet, but its 17 Jul 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98088355
- Mark type
- Stylized text
- Filed
- 17 Jul 2023
- Published for opposition
- 30 Apr 2024
- Attorney of record
- Bret E. Field
Goods and services
- Class 001 — Chemicals: Chemical and biochemical preparations for scientific purposes, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for laboratory and experimentation purposes, in particular for conducting experimental assays, other than for medical or veterinary purposes; reagents for scientific and research use, namely, reagents such as proteins and nucleic acids for modifying cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages
- Class 005 — Pharmaceuticals: Pharmaceutical preparations, in particular in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; living cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; biological preparations in the form of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; therapeutic pharmaceuticals utilizing cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages in the treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections; cell preparations such as T cells, NK cells, NKT cells, iNKT cells, or macrophages for treatment of immune-oncological disorders, cancer, hyperproliferative diseases, and infections
- Class 042 — Scientific and technological services: Scientific and technological services, namely, scientific research, analysis and testing in the field of biology, pharmaceuticals and cell therapy; biological research and development; medical, pharmaceutical and biotechnological research
- Class 044 — Medical, beauty and agricultural services: Medical services, in particular in the field of immunotherapy, in particular in the field of immuno-oncology; medical services in the field of hyperproliferative diseases; medical services in the field of cancer; medical services in the field of anti-infectives; in particular all of the aforesaid services related to the use of protein, nucleic acid, or cells such as T cells, NK cells, NKT cells, iNKT cells, or macrophages
Owner
- NKILT Therapeutics, Inc., Springfield, NJ, US
- NKILT Therapeutics, Inc., Springfield, NJ, US
Prosecution history
- 29 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Dec 2025 — SOU EXTENSION 3 GRANTED
- 23 Dec 2025 — SOU EXTENSION 3 FILED
- 23 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 03 Jul 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jul 2025 — SOU EXTENSION 2 GRANTED
- 25 Jun 2025 — SOU EXTENSION 2 FILED
- 25 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 02 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Apr 2025 — SOU EXTENSION 1 GRANTED
- 16 Dec 2024 — SOU EXTENSION 1 FILED
- 31 Mar 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 16 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 25 Jun 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 30 Apr 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED